IPF Progression

IPF progression1,3

IPF progression chart image

IPF progression and acute IPF exacerbations1,3

IPF progression and acute IPF exacerbations chart image

IPF and FVC decline3,16-20

IPF and FVC decline chart image

FVC can be used as an objective measure of IPF disease progression, and a ≥10% FVC decline over 12 months has traditionally been used as a predictor of mortality risk.1,21-24 One study showed that a ≥10% FVC decline at 12 months was linked to a ≥2.4x greater risk of mortality.24 Another study showed that a 5%-10% decline in FVC at 6 months might indicate increased mortality risk.25

Limited treatment options have made determining an optimal intervention strategy challenging.1 There has been a high need for a treatment option that can effectively slow the progression of IPF.1

Despite medications that have been used to treat IPF, there is a high unmet need for an effective treatment that can slow disease progression.1

References

  1. Raghu G, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183:788–824.
  2. Adamali HI., et al. Non-pharmacological treatment of idiopathic pulmonary fibrosis. Curr Respir Care Rep 2012;1:208–215.
  3. Ley B., et al. Clinical course and prediction of survival in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2011;183:431–440.
  4. Navaratnam V., et al. The rising incidence of idiopathic pulmonary fibrosis in the U.K. Thorax 2011;66:462–467.
  5. Selman M, et al. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 2001;134:136–151.
  6. Selman M., et al. Accelerated variant of idiopathic pulmonary fibrosis: clinical behavior and gene expression pattern. PloS One 2007;2:e482.
  7. Song JW., et al. Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome. Eur Respir J 2011;37:356–363.
  8. Collard HR., et al. Patient experiences with pulmonary fibrosis. Respir Med 2007;101:1350–1354.
  9. Parambil JG., et al. Histopathologic features and outcome of patients with acute exacerbation of idiopathic pulmonary fibrosis undergoing surgical lung biopsy. Chest 2005;128:3310–3315.
  10. Reddel HK., et al. An official American Thoracic Society/European Respiratory Society statement: asthma control and exacerbations: standardizing endpoints for clinical asthma trials and clinical practice. Am J Respir Crit Care Med 2009;180:59–99.
  11. GOLD. Global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disorder. 2014.
  12. Groenewegen KH., et al. Mortality and mortality-related factors after hospitalization for acute exacerbation of COPD. Chest 2003;124:459–467.
  13. Krishnan V., et al. Mortality in patients hospitalized for asthma exacerbations in the United States. Am J Respir Crit Care Med 2006;174:633–638.
  14. Kim DS., et al. Acute exacerbation of idiopathic pulmonary fibrosis: frequency and clinical features. Eur Respir J 2006;27:143–150.
  15. Sakamoto K., et al. Acute exacerbation of idiopathic pulmonary fibrosis as the initial presentation of the disease. Eur Respir Rev Off J Eur Respir Soc 2009;18:129–132.
  16. Griffith KA., et al. Predictors of loss of lung function in the elderly: the Cardiovascular Health Study. Am J Respir Crit Care Med 2001;163:61–68.
  17. Alexeeff SE., et al. Ozone exposure, antioxidant genes, and lung function in an elderly cohort: VA normative aging study. Occup Environ Med 2008;65:736–742.
  18. Richeldi L., et al. Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis. N Engl J Med 2011;365:1079–1087.
  19. CYENDIV® India pack insert version dated 10th August 2018.
  20. King TE., et al. Treatments for idiopathic pulmonary fibrosis. N Engl J Med 2014;371:783–784.
  21. du Bois RM., et al. Forced vital capacity in patients with idiopathic pulmonary fibrosis: test properties and minimal clinically important difference. Am J Respir Crit Care Med 2011;184:1382–1389.
  22. Raghu G., et al. Idiopathic pulmonary fibrosis: clinically meaningful primary endpoints in phase 3 clinical trials. Am J Respir Crit Care Med 2012;185:1044–1048.
  23. Richeldi L., et al. Relative versus absolute change in forced vital capacity in idiopathic pulmonary fibrosis. Thorax 2012;67:407–411.
  24. Schmidt SL., et al. Predicting pulmonary fibrosis disease course from past trends in pulmonary function. Chest 2014;145:579–585.
  25. Zappala CJ., et al. Marginal decline in forced vital capacity is associated with a poor outcome in idiopathic pulmonary fibrosis. Eur Respir J 2010;35:830–836.